 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 02, 2021 GLOBE NEWSWIRE -- ORIC Pharmaceuticals, Inc. Nasdaq: ORIC, a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the following investor conferences in March: 